Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Real World Population- Based Data from Nationwide Registry Support the Existence of Accelerated Phase in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients Even in Tyrosine Kinase Inhibitors (TKIs) Era

Blood (2023) 142 (Supplement 1): 3166.

https://doi.org/10.1182/blood-2023-174455

Published: 2023

Journal Articles

Somatic Mutations in Cancer-Related Genes Were Observed More Frequently in AYA CML Patients Compared to Elderly at Diagnosis, Whereas the Frequency Was Markedly Higher in Elderly Patients during TKI Treatment

Jitka Krizkova, Vaclava Polivkova, Nikola Curik, Adam Laznicka, Adela Benesova, Hana Klamova, Marketa Stastna Markova, Dana Srbova, Jan Zuna, Marketa Zaliova, Jan Trka, Pavel Semerak, Tomas Kalina, Cyril Salek, Katerina Machova Polakova

Blood (2023) 142 (Supplement 1): 4544.

https://doi.org/10.1182/blood-2023-189017

Published: 2023

Journal Articles

Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry

Blood (2022) 140 (Supplement 1): 818–820.

https://doi.org/10.1182/blood-2022-162252

Published: 2022

Journal Articles

The Rate of Cellular Energy Production of Muscle Cells Is Attenuated By Carnitine Intracellular Deficiency Caused By Imatinib Treatment

Pavel Burda, Alzbeta Hlavackova, Vaclava Polivkova, Nikola Curik, Hana Klamová, Jitka Koblihova, Jiri Suttnar, Katerina Machova

Blood (2021) 138 (Supplement 1): 3609.

https://doi.org/10.1182/blood-2021-152516

Published: 2021

Journal Articles

Half: A Prospective Multi-Centre Phase II Clinical Trial Evaluating the Efficacy and Safety of Tyrosine Kinase Inhibitors' Discontinuation after Two-Step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission

Blood (2021) 138 (Supplement 1): 3606.

https://doi.org/10.1182/blood-2021-146221

Published: 2021

Journal Articles

Clonal Hematopoiesis with Somatic Mutations in "AYA" Generation of Patients with Chronic Myeloid Leukemia

Jitka Koblihova, Vaclava Polivkova, Adela Benesova, Hana Zizkova, Nikola Curik, Monika Pepek, Tomasz Stoklosa, MD PhD, Marketa Markova Stastna, Hana Klamová, Dana Srbova, Katerina Machova

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-140725

Published: 2020

Journal Articles

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1647.

https://doi.org/10.1182/blood-2019-129710

Published: 2019

Journal Articles

Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database

Blood (2019) 134 (Supplement_1): 498.

https://doi.org/10.1182/blood-2019-124430

Published: 2019

Journal Articles

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

Eva Koriťáková, RNDr., PhD, Michael Doubek, MD PhD, Edgar Faber, MD PhD, Daniela Žáčková, MD PhD, Jan M. Horáček, MD PhD, Petra Bělohlávková, MD PhD, Eduard Cmunt, MD PhD, František Folber, MD PhD, Pavel Jindra, MD PhD, Hana Klamová, MD PhD, Zdeněk Kořístek, MD PhD, Lukáš Stejskal, MD, Tomáš Szotkowski, MD PhD, Cyril Šálek, MD PhD, Renata Kellnerová, MD PhD, Marika Chrápavá, Mgr.

Blood (2019) 134 (Supplement_1): 5905.

https://doi.org/10.1182/blood-2019-126395

Published: 2019

Journal Articles

DNA Analysis of Mutations in the Kinase Domain of BCR-ABL1 By Allele-Specific Digital PCR Is Highly Sensitive and Refines Prediction of Kinetics of Resistant CML Clones

Vaclava Polivkova, Nikola Curik, Hana Zizkova, Adela Benesova, Pavel Burda, Pavla Pecherkova, Eliska Motlova, Jana Brezinova, Sarka Ransdorfova, Hana Klamova, Lenka Hovorkova, Jan Zuna, Thomas Ernst, Simona Soverini, PhD, Katerina Machova

Blood (2018) 132 (Supplement 1): 1743.

https://doi.org/10.1182/blood-2018-99-119710

Published: 2018

Journal Articles

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Susanne Saussele, MD, Johan Richter, MD PhD, Joelle Guilhot, PhD, Henrik Hjorth-Hansen, MD, Antonio Medina de Almeida, MD PhD, Jeroen J. W. M. Janssen, MD, Jiri Mayer, Prof, MD SCs, Perttu Koskenvesa, MD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Strömberg, MD PhD, Juan Luis Steegmann, MD PhD, Hanne Vestergaard, MD, Hans Ehrencrona, MD PhD, Veli Kairisto, Kateřina Machová Poláková, PhD, Martin Müller, MD, Satu Mustjoki, MDPhD, Marc G. Berger, MD PhD, Philippe Rousselot, Martine Escoffre-Barbe, MD, Gabriel Etienne, MD PhD, Jolanta Dengler, MD, Françoise Rigal-Huguet, MD, Nikolas von Bubnoff, MD, Hana Klamova, MD, Edgar Faber, MD, François Guilhot, MD, Kourosh Lotfi, MD, Delphine Rea, MD, Tim H. Brümmendorf, MD, Gorgine de Greef, MD, Leif Stenke, MD, Franck Emmanuel Nicolini, MD PhD, Laurence Legros, MD PhD, Andreas Burchert, MD, Jaroslava Voglová, MD, Aude Charbonnier, MD, Emmanuel Gyan, MDPhD, Maria-Elisabeth Goebeler, MD, Peter E. Westerweel, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 313.

https://doi.org/10.1182/blood.V130.Suppl_1.313.313

Published: 2017

Journal Articles

DNA Based Detection and Quantification of BCR-ABL1 Gene Using Patient-Specific qPCR and Droplet Digital PCR Tests in Chronic Myeloid Leukemia

Hana Zizkova, Eliska Motlova, Karla Zemanova, Hana Klamova, Lenka Hovorkova, Jan Zuna, Jan Zach, Susanne Saussele, Francois-Xavier Mahon, Katerina Machova Polakova

Blood (2015) 126 (23): 4043.

https://doi.org/10.1182/blood.V126.23.4043.4043

Published: 2015

Journal Articles

Patients with Chronic Myeloid Leukemia Show Different Modulation of MYB-Dependent Oncogenic Pathway in the Course of Hematopoietic Differentiation upon Sensitivity to the TKI Treatment

Klara Srutova, Nikola Curik, Koblihova Jitka, Filipp Savvulidi, Hana Klamova, Danilo Perrotti, Tomas Stopka, Katerina Machova Polakova

Blood (2015) 126 (23): 1243.

https://doi.org/10.1182/blood.V126.23.1243.1243

Published: 2015

Journal Articles

SNPs in the Promoter of the Gene Encoding Transmembrane Transporter SLC22A4 (hOCTN1) Are Significantly Associated with an Alteration of Gene Expression and with Resistance to the Imatinib Treatment in Chronic Myeloid Leukemia

Monika Jaruskova, Rajna Hercog, Nikola Curik, Vladimir Benes, Hana Klamova, Katerina Machova Polakova

Blood (2015) 126 (23): 2463.

https://doi.org/10.1182/blood.V126.23.2463.2463

Published: 2015

Journal Articles

Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study

Racil Zdenek, Petra Belohlavkova, Petr Cetkovsky, Edgar Faber, Hana Klamova, Malaskova Ludmila, Tomasz Sacha, MD PhD, Voglova Jaroslava, Daniela Zackova, Pavel Zak, Jiri Mayer

Blood (2014) 124 (21): 1813.

https://doi.org/10.1182/blood.V124.21.1813.1813

Published: 2014

Journal Articles

Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain

Blood (2013) 122 (21): 3986.

https://doi.org/10.1182/blood.V122.21.3986.3986

Published: 2013

Journal Articles

Algorithms and Processing Pipeline For Error Correction and Detection Of Significant Mutations In The Kinase Domain Of BCR-ABL Analyzed By Next-Generation Sequencing: Implications For Clinical Practice Of Chronic Myeloid Leukemia

Katerina Machova Polakova, Vojtech Kulvait, Jana Linhartova, Adela Brouckova, Simona Soverini, Monika Jaruskova, Caterina de Benedittis, Torsten Haferlach, MD, Michele Baccarani, MD, Giovanni Martinelli, MD, Alexander Kohlmann, PhD, Hana Klamova

Blood (2013) 122 (21): 3987.

https://doi.org/10.1182/blood.V122.21.3987.3987

Published: 2013

Journal Articles

Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy

Simona Soverini, Caterina De Benedittis, Katerina Machova Polakova, Adela Brouckova, Fausto Castagnetti, Gabriele Gugliotta, Francesca Palandri, Cristina Papayannidis, MD, Ilaria Iacobucci, Claudia Venturi, Manuela Mancini, Elisa Leo, Hana Klamova, Stefania Paolini, Domenico Russo, Gianantonio Rosti, Michele Baccarani, MD, Michele Cavo, Giovanni Martinelli

Blood (2013) 122 (21): 380.

https://doi.org/10.1182/blood.V122.21.380.380

Published: 2013

Journal Articles

Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

Blood (2013) 122 (9): 1634–1648.

https://doi.org/10.1182/blood-2013-03-487728

Published: 2013

Includes: Supplemental data

Journal Articles

Ultradeep-Amplicon Pyrosequencing for Mutation Detection in the Kinase Domain of BCR-ABL Revealed Artificial Low-Level Variants That Need to Be Avoided for Relevant Mutational Data Interpretation

Adela Brouckova, Simona Soverini, Caterina De Benedittis, Hana Klamova, Cyril Salek, Marek Trneny, MD, Michele Baccarani, MD, Giovanni Martinelli, Katerina Machova Polakova

Blood (2012) 120 (21): 1396.

https://doi.org/10.1182/blood.V120.21.1396.1396

Published: 2012

NARROW

Real World Population- Based Data from Nationwide Registry Support the Existence of Accelerated Phase in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients Even in Tyrosine Kinase Inhibitors (TKIs) Era

Somatic Mutations in Cancer-Related Genes Were Observed More Frequently in AYA CML Patients Compared to Elderly at Diagnosis, Whereas the Frequency Was Markedly Higher in Elderly Patients during TKI Treatment

Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry

The Rate of Cellular Energy Production of Muscle Cells Is Attenuated By Carnitine Intracellular Deficiency Caused By Imatinib Treatment

Half: A Prospective Multi-Centre Phase II Clinical Trial Evaluating the Efficacy and Safety of Tyrosine Kinase Inhibitors' Discontinuation after Two-Step Dose Reduction in Patients with Chronic Myeloid Leukemia in Deep Molecular Remission

Clonal Hematopoiesis with Somatic Mutations in "AYA" Generation of Patients with Chronic Myeloid Leukemia

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database

Ponatinib Treatment in CML and Ph+ ALL Patients: Real-Life Data from the Czech Registries

DNA Analysis of Mutations in the Kinase Domain of BCR-ABL1 By Allele-Specific Digital PCR Is Highly Sensitive and Refines Prediction of Kinetics of Resistant CML Clones

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

DNA Based Detection and Quantification of BCR-ABL1 Gene Using Patient-Specific qPCR and Droplet Digital PCR Tests in Chronic Myeloid Leukemia

Patients with Chronic Myeloid Leukemia Show Different Modulation of MYB-Dependent Oncogenic Pathway in the Course of Hematopoietic Differentiation upon Sensitivity to the TKI Treatment

SNPs in the Promoter of the Gene Encoding Transmembrane Transporter SLC22A4 (hOCTN1) Are Significantly Associated with an Alteration of Gene Expression and with Resistance to the Imatinib Treatment in Chronic Myeloid Leukemia

Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study

Minor Subclones Harboring Small Insertions and Deletions Probably Due To Aberrant Splicing Can Frequently Be Detected By Deep Sequencing of The BCR-ABL Kinase Domain

Algorithms and Processing Pipeline For Error Correction and Detection Of Significant Mutations In The Kinase Domain Of BCR-ABL Analyzed By Next-Generation Sequencing: Implications For Clinical Practice Of Chronic Myeloid Leukemia

Ultra Deep Sequencing (UDS) Allows More Sensitive Detection Of Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL Mutations That Would Influence Therapeutic Decision At The Time Of Switchover To Second- Or Third-Line Therapy

Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

Ultradeep-Amplicon Pyrosequencing for Mutation Detection in the Kinase Domain of BCR-ABL Revealed Artificial Low-Level Variants That Need to Be Avoided for Relevant Mutational Data Interpretation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only